Antisense DNA directed against C-myc oncogene blocks tumor growth in normal mice. The first clinical trials of oligonucleotide therapeutics have demonstrated antisense efficacy in patients against follicular lymphoma, chronic myelogenous leukemia, cytomegalovirus and Crohn's disease. The central hypothesis of this application is that second and third generation derivatives of ant-c-myc DNAs will display greater systemic potency than phosphorothioates in animal models of c-myc- dependent lymphomas and other myc dependent malignancies. Previous work under this grant has demonstrated efficacy of a variety of DNA derivatives, against a variety of c-myc mRNA targets, in malignant cells growing in culture and in murine hosts. Over the next five years, these successes will be translated into lead compounds. 1. More sensitive c-myc mRNA targets will be identified. Radio-labeled c-myc mRNA targets will be hybridized to overlapping antisense DNA oligomers immobilized on polypropylene chips. To test the hybridization results, the antisense efficacy of a series of overlapping anti-c-myc oligomers will be measured in cultured lymphoma cells. 2. The potency of anti-c-myc DNAs will be increased. For the best sequences identified in 1., anti-c-myc DNA chimeras will be synthesized with terminal phosphorothioates and central methylphosphonates, or 2'-O-methyl residues. Peptide nucleic acid derivatives will also be prepared, with cyclic peptide ligands designed for receptor specific cellular uptake. For each lead compound, sequence specificity and mechanism will be tested with 1-4 mismatches. Aptameric effects will be screened. 3. The pharmacodynamics of anti-c-myc DNAs will be optimized. (a) Tumor cells from Eu-myc lymphoma cells, transplanted into the immuno-compatible parental strain, will be treated with the most potent anti-c-myc DNA derivatives above. Tumor size, mRNA, and antigen levels will be studied as a function of dose and schedule. (b) Intraperitoneal, subcutaneous, subcutaneous depot, and oral administration will be compared. (c) The most potent anti-c-myc DNAs will be tested for adjuvant therapy of residual disease, by allowing transplanted lymphoma cells to establish for varying times prior to initiation of therapy. 4. The safety of anti-c-myc DNAs will be evaluated. (a) Administration, distribution, metabolism, and excretion of new anti-c-myc derivatives will be compared to elucidate variation of potency with route. (b) Body weight, splenomegaly, cytokines, complement, liver enzymes and complete blood count will be compared to identify the anti-c-myc derivative with the greatest therapeutic ration. 5. The breadth of spectrum of anti-c-myc DNAs will be determined. Candidate sequences will be tested for efficacy against xenografts of human (a) ST486 Burkitt's lymphoma cells (b) U937 erythroleukemia cells (c) BT474 breast cancer cells (d) COLO320 colon cancer cells and (e) A549 lung cancer cells. The efficacy and potency of combination therapy will be evaluated. Anti-c-myc DNA's will be tested in combination or alteratively with (a) immunostimulatory DNAs or (b) anti- proliferative compounds. The lead compounds resulting from these studies will then be translated to a separate collaborative application for a Phase I/II clinical trial.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042960-13
Application #
6172524
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Yovandich, Jason L
Project Start
1987-04-15
Project End
2003-06-30
Budget Start
2000-07-01
Budget End
2003-06-30
Support Year
13
Fiscal Year
2000
Total Cost
$369,730
Indirect Cost
Name
Thomas Jefferson University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Wickstrom, Eric (2015) DNA and RNA derivatives to optimize distribution and delivery. Adv Drug Deliv Rev 87:25-34
Tian, X; Chakrabarti, A; Amirkhanov, N et al. (2007) Receptor-mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochem Soc Trans 35:72-6
Tian, Xiaobing; Chakrabarti, Atis; Amirkhanov, Nariman V et al. (2005) External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras. Ann N Y Acad Sci 1059:106-44
Thakur, Mathew L; Aruva, Mohan R; Gariepy, Jean et al. (2004) PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med 45:1381-9
Hargis, M T; Storck, C W; Wickstrom, E et al. (2004) Hsp27 anti-sense oligonucleotides sensitize the microtubular cytoskeleton of Chinese hamster ovary cells grown at low pH to 42 degrees C-induced reorganization. Int J Hyperthermia 20:491-502
Vorobjev, Pavel E; Smith, Janet B; Pyshnaya, Inna A et al. (2003) Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem 14:1307-13
Tian, Xiaobing; Aruva, Mohan R; Rao, Ponugoti S et al. (2003) Imaging oncogene expression. Ann N Y Acad Sci 1002:165-88
Urtishak, Karen A; Choob, Michael; Tian, Xiaobing et al. (2003) Targeted gene knockdown in zebrafish using negatively charged peptide nucleic acid mimics. Dev Dyn 228:405-13
Rao, P S; Tian, X; Qin, W et al. (2003) 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours. Nucl Med Commun 24:857-63
Smith, J B; Wickstrom, E (2000) Preclinical antisense DNA therapy of cancer in mice. Methods Enzymol 314:537-80

Showing the most recent 10 out of 30 publications